Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

0.9089 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56
Open 0.9089
Bid (Size) 0.8900 (1)
Ask (Size) 0.9488 (1)
Prev. Close 0.9089
Today's Range 0.9089 - 0.9089
52wk Range 0.6101 - 3.480
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best Digital Health Stocks for Personalized Medicine
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health. 
Via InvestorPlace
23andMe Reports Second Quarter Fiscal 2024 Financial Results
Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin 
From 23andMe, Inc.
Via GlobeNewswire

Performance

YTD
-56.72%
-56.72%
1 Month
+17.70%
+17.70%
3 Month
-17.37%
-17.37%
6 Month
-51.91%
-51.91%
1 Year
-67.07%
-67.07%

More News

Read More
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report FY2024 Second Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
Via FinancialNewsMedia
Exposures Product Safety
The Top 7 Stocks to Own During a Downturn
Via InvestorPlace
23andMe Under Siege: Hacker Reportedly Steals Millions Of Profiles In Genetic Data Heist
Via Benzinga
Topics Hacking
Exposures Information Security
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
From 23andMe, Inc.
Via GlobeNewswire
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
From 23andMe, Inc.
Via GlobeNewswire
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Top 5 Health Care Stocks That May Explode In Q3
Via Benzinga
Why Olin Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Dell Technologies Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
From 23andMe, Inc.
Via GlobeNewswire
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why 23andMe Holding Stock Plummeted by 13% Today
Via The Motley Fool
23andMe Reports FY2024 First Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report FY2024 First Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
From 23andMe, Inc.
Via GlobeNewswire
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
From 23andMe, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.